All In Biotech

Drug Trial Radar · NCT06906471

A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Actual

Start

Jul 1, 2026

Primary completion

Oct 30, 2026

Study completion Nov 30, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS

Conditions

  • Prostate Cancer
  • Prostate Cancer (Adenocarcinoma)
  • Fluorescence Imaging

Interventions

  • AS1986NSDrug

    Single dose, IV, 100 µg of AS1986NS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of AS1986NSTime frame: Enrollment to 30 days post single infusion

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • HCA Florida Kendall Hospital

    Miami, Florida

  • Icahn School of Medicine at Mount Sinai (ISMMS)

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.